Integration of pediatric diets in the treatment of ALL

Mark R. Litzow, MD, discusses the talk he gave on initial treatment options for patients with acute lymphoblastic leukemia at the National Comprehensive Cancer Network’s 2022 Annual Meeting: Malignant Hematologies.

Mark R. Litzow, MD, Chairman, Professor of Medicine, Division of Hematology, Mayo Clinic, discusses the presentation he gave on initial treatment options for patients with acute lymphoblastic leukemia (ALL) at the National Comprehensive Cancer Network Annual Meeting 2022: Malignant Hematologies.

After years of little to no new developments in the ALL space, experts have found that young adults up to age 40 with ALL can tolerate pediatric treatment regimens. By providing patients with additional doses of these agents, better survival outcomes have been observed.

As young adults and pediatric patients are able to tolerate these intensive regimens, they are now beginning to be incorporated into the treatment of this patient population.

Transcription:

0:08 | I have focused in my talk on initial treatment options for patients with acute lymphoblastic leukemia and risk stratification. Some of the new developments in ALL, and there have been many that have been very exciting for us after many years of stagnation where we didn’t have many new treatments, one of the important things we learned is that in young adults with ALL, they can tolerate treatment programs that have been used in children, thus pediatric diets. These diets contain more drugs like vincristine, asparaginase and corticosteroids.

0:50 | It appears that extra doses of these drugs helped improve outcomes in children and now we have found in young adults. Young adults include patients up to 40 years old and, in some circumstances, up to 50 or 55 years old. They can tolerate these intensive diets and we see better results, so better survival and fewer relapses. We have incorporated these types of treatment regimens into the treatment of younger patients with acute lymphoblastic leukemia.

Comments are closed.